Form 4: Cue Biopharma Director Awarded Stock Options

Cue Biopharma's Director, Pasha Sarraf, was granted 24,400 stock options at an exercise price of $0.34, vesting in one year.

Summary

• Pasha Sarraf, a Director at Cue Biopharma, Inc. (CUE), was granted 24,400 stock options.
• The options have an exercise price of $0.34 per share.
• The grant date for these options was January 2, 2026.
• The options will become fully exercisable on January 2, 2027, which is the first anniversary of the grant date.
• The expiration date for these options is January 1, 2036.
• This award is part of the Issuer's Director Compensation Policy.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. A routine compensation event that aligns director interests with shareholders, but does not provide new operational or financial performance data.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options were granted at an exercise price of $0.34, which could represent a future upside if the stock price increases above this value.

Risks

• The value of the stock options is dependent on the future performance of Cue Biopharma's stock price; if the stock price does not exceed the exercise price of $0.34, the options may expire worthless.

Future Outlook

The stock options are designed to incentivize future performance, with vesting tied to a one-year period, suggesting an expectation of continued director involvement and potential stock price appreciation.

Management Comments

• The stock option award was granted pursuant to the Issuer's Director Compensation Policy.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation, especially in companies like Cue Biopharma that may be in development stages.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in many public companies, particularly in growth-oriented sectors like biotechnology, to attract and retain talent and align interests.
• The vesting schedule (one year) is a common practice for director equity awards, ensuring continued engagement.
• The exercise price being set at a specific value ($0.34) is typical for options, reflecting a potential future value.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of director incentives with long-term stock performance.
• Director (Pasha Sarraf): Receives equity compensation, providing a direct financial interest in the company's stock appreciation.

Next Steps

• Pasha Sarraf will be able to exercise the 24,400 stock options starting January 2, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director as part of their compensation. While it aligns director interests with shareholders, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on existing fundamental analysis.

Keywords

Cue Biopharma, CUE, Stock Option, Director Compensation, Insider Transaction, Equity Award, Pasha Sarraf